Tesamorelin / CJC-1295 / Ipamorelin

This blend combines two GHRH-pathway materials with a ghrelin-receptor agonist. There is no established scientific rationale for assuming that combining overlapping secretagogues improves reproducibility or safety.

Component-level activity converges on pituitary growth-hormone release and downstream IGF-1 signaling.

Blend-level evidence is unestablished.

Blend, No established blend evidence

Overlapping mechanisms, exact identity, receptor dynamics, stability, and endocrine feedback make extrapolation from single-agent studies unreliable.

Potential concerns include excessive endocrine stimulation, glucose dysregulation, edema, cardiovascular effects, and elevated IGF-1.

No FDA-approved combination drug product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.